Benitec Biopharma (BNTC) EBITDA (2019 - 2025)

Benitec Biopharma has reported EBITDA for 7 years, with the latest figure at -$13.4 million in Q4 2025.

• Quarterly EBITDA fell 23.8% year-over-year to -$13.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$48.3 million (down 83.94% YoY) and the FY2025 annual result came in at -$41.8 million, down 85.7% from the prior year.
• EBITDA fell to -$13.4 million in Q4 2025 per BNTC's latest filing, from -$9.8 million in the prior quarter.
• Over five years, EBITDA peaked at -$3.5 million in Q1 2022 and troughed at -$15.3 million in Q1 2025.
• A 5-year average of -$6.6 million and a median of -$5.2 million in 2021 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2025: EBITDA increased 8.78% in 2022, then tumbled 270.32% in 2025.
• Over 5 years, EBITDA stood at -$4.8 million in 2021, then decreased by 16.03% to -$5.6 million in 2022, then declined by 23.48% to -$6.9 million in 2023, then tumbled by 55.98% to -$10.8 million in 2024, then slipped by 23.8% to -$13.4 million in 2025.
• According to Business Quant data, EBITDA over the past three periods registered -$13.4 million, -$9.8 million, and -$9.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.